Aminoclay–lipid hybrid composite as a novel drug carrier of fenofibrate for the enhancement of drug release and oral absorption

Liang Yang, Yating Shao, Hyo-Kyung Han BK Plus Project Team, College of Pharmacy, Dongguk University, Goyang, South Korea Abstract: This study aimed to prepare the aminoclay–lipid hybrid composite to enhance the drug release and improve the oral bioavailability of poorly water-soluble fe...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yang L, Shao Y, Han HK
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://doaj.org/article/45c8565ec42b4566bc88c3d1284e4dbe
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:45c8565ec42b4566bc88c3d1284e4dbe
record_format dspace
spelling oai:doaj.org-article:45c8565ec42b4566bc88c3d1284e4dbe2021-12-02T03:05:18ZAminoclay–lipid hybrid composite as a novel drug carrier of fenofibrate for the enhancement of drug release and oral absorption1178-2013https://doaj.org/article/45c8565ec42b4566bc88c3d1284e4dbe2016-03-01T00:00:00Zhttps://www.dovepress.com/aminoclayndashlipid-hybrid-composite-as-a-novel-drug-carrier-of-fenofi-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Liang Yang, Yating Shao, Hyo-Kyung Han BK Plus Project Team, College of Pharmacy, Dongguk University, Goyang, South Korea Abstract: This study aimed to prepare the aminoclay–lipid hybrid composite to enhance the drug release and improve the oral bioavailability of poorly water-soluble fenofibrate. Antisolvent precipitation coupled with an immediate freeze-drying method was adopted to incorporate fenofibrate into aminoclay–lipid hybrid composite (ALC). The optimal composition of the ALC formulation was determined as the ratios of aminoclay to krill oil of 3:1 (w/w), krill oil to fenofibrate of 2:1 (w/w), and antisolvent to solvent of 6:4 (v/v). The morphological characteristics of ALC formulation were determined using scanning electron microscopy, differential scanning calorimetry, and X-ray powder diffraction, which indicated microcrystalline state of fenofibrate in ALC formulation. The ALC formulation achieved almost complete dissolution within 30 minutes, whereas the untreated powder and physical mixture exhibited less than 15% drug release. Furthermore, ALC formulation effectively increased the peak plasma concentration (Cmax) and area under the curve (AUC) of fenofibric acid (an active metabolite) in rats by approximately 13- and seven-fold, respectively. Furthermore, ALC formulation exhibited much lower moisture sorption behavior than the lyophilized formulation using sucrose as a cryoprotectant. Taken together, the present findings suggest that ALC formulation is promising for improving the oral absorption of poorly soluble fenofibrate. Keywords: aminoclay, omega-3 phospholipids, fenofibrate, drug release, oral absorption Yang LShao YHan HKDove Medical PressarticleAminoclayOmega-3 phospholipidsFenofibrateDrug releaseOral absorptionMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2016, Iss default, Pp 1067-1076 (2016)
institution DOAJ
collection DOAJ
language EN
topic Aminoclay
Omega-3 phospholipids
Fenofibrate
Drug release
Oral absorption
Medicine (General)
R5-920
spellingShingle Aminoclay
Omega-3 phospholipids
Fenofibrate
Drug release
Oral absorption
Medicine (General)
R5-920
Yang L
Shao Y
Han HK
Aminoclay–lipid hybrid composite as a novel drug carrier of fenofibrate for the enhancement of drug release and oral absorption
description Liang Yang, Yating Shao, Hyo-Kyung Han BK Plus Project Team, College of Pharmacy, Dongguk University, Goyang, South Korea Abstract: This study aimed to prepare the aminoclay–lipid hybrid composite to enhance the drug release and improve the oral bioavailability of poorly water-soluble fenofibrate. Antisolvent precipitation coupled with an immediate freeze-drying method was adopted to incorporate fenofibrate into aminoclay–lipid hybrid composite (ALC). The optimal composition of the ALC formulation was determined as the ratios of aminoclay to krill oil of 3:1 (w/w), krill oil to fenofibrate of 2:1 (w/w), and antisolvent to solvent of 6:4 (v/v). The morphological characteristics of ALC formulation were determined using scanning electron microscopy, differential scanning calorimetry, and X-ray powder diffraction, which indicated microcrystalline state of fenofibrate in ALC formulation. The ALC formulation achieved almost complete dissolution within 30 minutes, whereas the untreated powder and physical mixture exhibited less than 15% drug release. Furthermore, ALC formulation effectively increased the peak plasma concentration (Cmax) and area under the curve (AUC) of fenofibric acid (an active metabolite) in rats by approximately 13- and seven-fold, respectively. Furthermore, ALC formulation exhibited much lower moisture sorption behavior than the lyophilized formulation using sucrose as a cryoprotectant. Taken together, the present findings suggest that ALC formulation is promising for improving the oral absorption of poorly soluble fenofibrate. Keywords: aminoclay, omega-3 phospholipids, fenofibrate, drug release, oral absorption 
format article
author Yang L
Shao Y
Han HK
author_facet Yang L
Shao Y
Han HK
author_sort Yang L
title Aminoclay–lipid hybrid composite as a novel drug carrier of fenofibrate for the enhancement of drug release and oral absorption
title_short Aminoclay–lipid hybrid composite as a novel drug carrier of fenofibrate for the enhancement of drug release and oral absorption
title_full Aminoclay–lipid hybrid composite as a novel drug carrier of fenofibrate for the enhancement of drug release and oral absorption
title_fullStr Aminoclay–lipid hybrid composite as a novel drug carrier of fenofibrate for the enhancement of drug release and oral absorption
title_full_unstemmed Aminoclay–lipid hybrid composite as a novel drug carrier of fenofibrate for the enhancement of drug release and oral absorption
title_sort aminoclay–lipid hybrid composite as a novel drug carrier of fenofibrate for the enhancement of drug release and oral absorption
publisher Dove Medical Press
publishDate 2016
url https://doaj.org/article/45c8565ec42b4566bc88c3d1284e4dbe
work_keys_str_mv AT yangl aminoclayndashlipidhybridcompositeasanoveldrugcarrieroffenofibratefortheenhancementofdrugreleaseandoralabsorption
AT shaoy aminoclayndashlipidhybridcompositeasanoveldrugcarrieroffenofibratefortheenhancementofdrugreleaseandoralabsorption
AT hanhk aminoclayndashlipidhybridcompositeasanoveldrugcarrieroffenofibratefortheenhancementofdrugreleaseandoralabsorption
_version_ 1718401981448454144